zafirlukast and Abraxane Interactions

Interactions between zafirlukast and Abraxane (paclitaxel protein-bound)

zafirlukast and paclitaxel protein-bound (Moderate Drug-Drug)

MONITOR: Theoretically, coadministration with drugs that are inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which is metabolized by these isoenzymes.

MANAGEMENT: Clinicians should recognize the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression (eg., pallor, dizziness, fatigue, lethargy, easy bruising or bleeding, or signs of infection such as fever, chills, or sore throat) or neuropathy (e.g., visual disturbances and burning, tingling, or numbness in the hands and feet).